Used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It functions as a tyrosine kinase inhibitor, targeting the epidermal growth factor receptor (EGFR), which is often overactive in certain cancers. By blocking EGFR signaling, it helps slow or stop tumor growth. Administered orally, it is often prescribed for patients with specific EGFR mutations, particularly in advanced stages of NSCLC. Also used in combination with other chemotherapeutic agents for pancreatic cancer to improve survival rates. Its targeted action reduces damage to healthy cells compared to traditional chemotherapy, leading to fewer side effects and better patient outcomes in responsive cases.